ANGO

AngioDynamics Inc. Q1 Loss Decreases, Beats Estimates

(RTTNews) - AngioDynamics Inc. (ANGO) released Loss for first quarter that Decreased from last year and beat the Street estimates.

The company's earnings came in at -$10.903 million, or -$0.26 per share. This compares with -$12.798 million, or -$0.31 per share, last year.

Excluding items, AngioDynamics Inc. reported adjusted earnings of -$4.179 million or -$0.10 per share for the period.

Analysts on average had expected the company to earn -$0.12 per share. Analysts' estimates typically exclude special items.

The company's revenue for the period rose 12.2% to $75.711 million from $67.491 million last year.

AngioDynamics Inc. earnings at a glance (GAAP) :

-Earnings: -$10.903 Mln. vs. -$12.798 Mln. last year. -EPS: -$0.26 vs. -$0.31 last year. -Revenue: $75.711 Mln vs. $67.491 Mln last year.

Looking ahead, for fiscal 2026, the company has revised up its outlook, where it expects revenue better than Street view.

Excluding items, AngioDynamics now expects a loss of $0.33 to $0.23 per share, compared with the prior guidance for a loss of $0.35 to $0.25 per share. Adjusted EBITDA is now anticipated to be $6 million to $10 million as against $3 million to $8 million previously.

For the full year, the company now projects sales of $308 million to $313 million, higher than the previous guidance of $305 to $310 million.

Analysts, on average, forecast AngioDynamics to report an annual loss of $0.31 per share on revenue of $307.2 million. Analysts’ estimates typically exclude special items.

ANGO was up by 5.60% at $11.69 in the pre-market trade on the Nasdaq.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.